Skip to content
November 19, 2026
  • WhatsApp
  • Facebook
  • Twitter
  • Youtube
  • LinkedIn
  • Instagram
Business Quest

Business Quest

Focus on Enterprises and Innovation

  • HOME
  • BUSINESS
    • BANKING
    • FINANCE
    • INSURANCE
    • SME’s
    • REAL ESTATES
    • INVESTMENTS
    • ENERGY
    • RETAIL
  • CAPTAINS OF INDUSTRY
  • INNOVATION & ENTERPRISES
  • WOMEN & POWER
  • TECHNOLOGY
  • OPINION
    • Corporate News from Media OutReach Newswire
  • HOME
  • BUSINESS
    • BANKING
    • FINANCE
    • INSURANCE
    • SME’s
    • REAL ESTATES
    • INVESTMENTS
    • ENERGY
    • RETAIL
  • CAPTAINS OF INDUSTRY
  • INNOVATION & ENTERPRISES
  • WOMEN & POWER
  • TECHNOLOGY
  • OPINION
    • Corporate News from Media OutReach Newswire
Watch Online
  • Home
  • Corporate News from Media OutReach Newswire
  • AIM Vaccine has obtained clinical approval for two heavyweight products, creating new growth points for performance
  • Corporate News from Media OutReach Newswire

AIM Vaccine has obtained clinical approval for two heavyweight products, creating new growth points for performance

Media OutReach Newswire December 20, 2024
HONG KONG SAR – Media OutReach Newswire – 20 December 2024 – AIM Vaccine (06660.HK) has added good news to the research and development of its heavyweight single product. According to the announcement on December 19, the clinical trial approval for the Group’s suspension culture quadrivalent influenza vaccine (MDCK cells) with new technological route and second generation of highly-effective absorbed tetanus vaccine have been recently obtained from the National Medical Products Administration. AIM Vaccine was intensively applied for and won two more clinical trial approvals in this year, creating new growth driver for the company’s future performance.

According to the announcement, currently, all influenza vaccines available on the domestic market are produced using chicken embryo technology. There have not been cell-based influenza vaccines approved for marketing. Compared with the traditional chicken embryo influenza split vaccine, the influenza vaccine (MDCK cells) developed by the Group has been significantly improved in terms of production quality and safety.

The MDCK cells developed by AIM Vaccine has the characteristics of easy cultivation, fast proliferation and susceptibility to influenza virus, etc. By large-scale cultivation of influenza virus in MDCK cells, it can achieve higher production volume, more stable production quality and lower production cost. Furthermore, this product has robust capability to withstand virus mutations, and does not contain ovalbumin, significantly reducing the risk of allergic reactions.

Compared with the influenza vaccines (MDCK cells) developed by other domestic manufacturers, AIM Vaccine adopts the suspension culture method for cell culture, which can be cultivated in bioreactors at scale with low contamination risks and is conducive to large-scale industrial production.

According to the announcement, based on the research and development of the second generation of highly-effective absorbed tetanus vaccine, AIM Vaccine is actively promoting the research and development of diphtheria, tetanus and acellular pertussis – HIB combined vaccine (the “Tetravaccine”), pentavalent vaccine and other multidisease vaccine. Among them, the Tetravaccine is used to prevent invasive infections caused by pertussis, diphtheria, tetanus and Haemophilus Influenzae type b, and has the advantages of reducing the number of vaccinations for infants and young children, and enhancing the vaccination compliance of parents, infants and young children.

The two heavyweight vaccine products announced by AIM Vaccine successfully obtained clinical trial approval documents, and its research and development has entered a new stage. According to the data of China Insights Industry Consultancy Limited, China’s influenza vaccine market will reach approximately RMB20 billion and , the Chinese market size of the multidisease vaccine is expected to reach RMB10 billion in 2030. Therefore, the suspension culture quadrivalent influenza vaccine (MDCK cells) with new technological route and the Tetravaccine will further improve the company’s product pipeline after the market, help enrich the product pipeline, consolidate the industry position, and promote the continued rapid growth of performance.

AIM Vaccine has always focused on unmet clinical needs in key disease areas to advance vaccine development. This year is an intensive year for AIM Vaccine. Up to now, the company has obtained 17 clinical approvals and carried out 21 clinical trials, among which international cutting-edge technology products such as mRNA respiratory syncytial virus (RSV) vaccine (large age group) have also obtained clinical approvals. In addition, the 13-valent pneumonia conjugate vaccine has been accepted, and the serum-free iterative rabies vaccine has also submitted a pre-registration application for listing, and the upcoming blockbuster new product is expected to bring stable revenue growth.
Hashtag: #AIMVaccine

The issuer is solely responsible for the content of this announcement.

Post navigation

Previous Ministry of Commerce partners with renowned chef Wolfgang Puck to elevate Thai SELECT’s global recognition
Next Kenya Cane Delivers Unforgettable Experiences at Kenyan Fest

Related Stories

Indonesia and Chinese partners set out USD 63 billion in cooperation at APEC Shenzhen
  • Corporate News from Media OutReach Newswire

Indonesia and Chinese partners set out USD 63 billion in cooperation at APEC Shenzhen

November 18, 2026
APEC promo answers era’s question: Why does China lead global tech?
  • Corporate News from Media OutReach Newswire

APEC promo answers era’s question: Why does China lead global tech?

November 18, 2026
SenseTime Provides Business Update for the First Nine Months of 2026: Revenue Growth Accelerates, Gross Margin Continues to Improve and Full-Stack AI Commercialization Gathers Pace
  • Corporate News from Media OutReach Newswire

SenseTime Provides Business Update for the First Nine Months of 2026: Revenue Growth Accelerates, Gross Margin Continues to Improve and Full-Stack AI Commercialization Gathers Pace

November 18, 2026

Recent Comments

  • Absa Next unveils Investment Solutions featuring Absa Equity Fund on Absa Bank Kenya Unveils an Integrated Digital Finance Solution
  • ShafDB Closes 60 Billion Sustainable Bond to Finance Housing on S&P Global Ratings confirms ShafDB Sustainability Framework
  • Equity Group Plc delivers KES71.5Bn with 32pc growth Q3 2026 on Equity Group Plc Earnings Grows to KES45.5Bn Profit H1 2026
  • StanChart’s Signature CIO Funds earns 5-Star Morningstar Ratings on StanChart Bank Kenya Triumphs at Global Finance Awards 2026
  • DHL,RUBIS Energy Bring Shipping Services to Customers on Rubis Energy Kenya Eyes Boda Boda Sector through a Program

Connect with Us

  • WhatsApp
  • Facebook
  • Twitter
  • Youtube
  • LinkedIn
  • Instagram

You may have missed

Indonesia and Chinese partners set out USD 63 billion in cooperation at APEC Shenzhen
  • Corporate News from Media OutReach Newswire

Indonesia and Chinese partners set out USD 63 billion in cooperation at APEC Shenzhen

November 18, 2026
Jambojet Cuts Fuel Costs by 16pc through Data-Driven Operations
  • Air Safety
  • Aircraft
  • Airline
  • Aviation
  • Aviation Sector
  • BUSINESS
  • Flight
  • INNOVATION & ENTERPRISES
  • Investments
  • jets
  • Markets
  • operations
  • Professionals
  • Regional Markets

Jambojet Cuts Fuel Costs by 16pc through Data-Driven Operations

November 18, 2026
APEC promo answers era’s question: Why does China lead global tech?
  • Corporate News from Media OutReach Newswire

APEC promo answers era’s question: Why does China lead global tech?

November 18, 2026
GARVEE Launches 2026 Black Friday & Christmas Specials: Featuring Dream Holiday Gifts and Cozy Winter Living
  • Corporate News from Media OutReach Newswire

GARVEE Launches 2026 Black Friday & Christmas Specials: Featuring Dream Holiday Gifts and Cozy Winter Living

November 18, 2026

About Us

Our main focus is on quality Business news content that is verified and ready to be consumed by our users.

Our partners and readers alike are our heartbeat we value them in all that we do.

We offer an alternative as a mouthpiece to SMEs, entrepreneurs, and professionals on their daily long-term plans and milestone as well exchange the business ideas and success stories and to provide advertising services tailor-made to the needs and expectations of their products and services.

Join us in this endeavor to give you fast accurate and precise information as they develop.

 

 

Copyright ©2026 All rights reserved. | Businessquest by Geckoworks Ke_.